Exhibit 99.3

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

Key Data Readouts on Track for All Programs in 2024

Anticipated Cash Runway into Q1 2025

Edinburgh, United Kingdom, August 15, 2024 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2024 and provided an update on its broad clinical development program with its transformative ProTide therapeutics.

As of June 30, 2024, NuCana had cash and cash equivalents of £11.6 million compared to £12.9 million as of March 31, 2024 and £17.2 million at December 31, 2023. NuCana continues to advance its numerous clinical programs and reported a net loss of £7.0 million for the quarter ended June 30, 2024, as compared to a net loss of £5.4 million for the quarter ended June 30, 2023. Basic and diluted loss per ordinary share was £0.12 for the quarter ended June 30, 2024, as compared to £0.10 per ordinary share for the comparable quarter ended June 30, 2023.

“During the first half of the year, we remained focused on the execution of our clinical programs, all of which are on track for data updates this year,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “NUC-3373, a ProTide transformation of 5-FU, is currently being evaluated in three clinical studies: NuTide:323, a randomized, 182-patient Phase 2 study for the second-line treatment of patients with metastatic colorectal cancer; NuTide:302, a Phase 1/2 study in patients with metastatic colorectal cancer; and NuTide:303, a Phase 1b/2 study in patients with solid tumors and lung cancer. We are pleased to report that all three studies are progressing as planned, and we look forward to sharing data updates in the second half of 2024.”

Mr. Griffith continued: “In addition, NUC-7738, a ProTide transformation of a novel nucleoside analog, 3’-deoxyadenosine, is being assessed in the Phase 2 part of the ongoing Phase 1/2 NuTide:701 study in PD-1 inhibitor-resistant melanoma patients. Following a positive data update at the American Association for Cancer Research (AACR) Annual Meeting earlier this year, we plan to announce additional data at the upcoming European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17 in Barcelona, Spain.”

Mr. Griffith concluded, “Our commitment to improving treatment outcomes for patients with cancer is what drives us to advance our development programs. We expect to announce numerous important data readouts in the second half of this year and look forward to providing updates on our progress.”

2024 Anticipated Milestones

• NUC-3373 (a ProTide transformation of 5-FU)

In 2024, NuCana expects to:

• Announce data from the randomized Phase 2 (NuTide:323) study of NUFIRI + bevacizumab compared to the standard of care FOLFIRI + bevacizumab for the second-line treatment of patients with metastatic colorectal cancer;

• Announce data from the Phase 1b/2 (NuTide:302) study of NUFIRI + bevacizumab and NUFOX + bevacizumab for the second-line treatment of patients with metastatic colorectal cancer; and

• Announce data from the Phase 1b/2 (NuTide:303) modular study of NUC-3373 in combination with pembrolizumab in patients with solid tumors and in combination with docetaxel in patients with lung cancer.

• NUC-7738 (a ProTide transformation of 3’-deoxyadenosine)

In 2024, NuCana expects to:

• Announce data from the Phase 2 part of the Phase 1/2 study (NuTide:701) of NUC-7738 in combination with pembrolizumab in patients with melanoma.

About NuCana

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently being evaluated in three ongoing clinical studies: a Phase 1b/2 study (NuTide:302) in combination with leucovorin, irinotecan or oxaliplatin, and bevacizumab in patients with metastatic colorectal cancer; a randomized Phase 2 study (NuTide:323) in combination with leucovorin, irinotecan, and bevacizumab for the second-line treatment of patients with metastatic colorectal cancer; and a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. NUC-7738 is a transformation of 3’-deoxyadenosine, a novel anti-cancer nucleoside analog. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma.

Forward-Looking Statements

This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; and the sufficiency of the Company’s current cash, cash equivalents and marketable securities to fund its planned operations into Q1 2025. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

Unaudited Condensed Consolidated Statements of Operations

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2024			2023			2024			2023
	(in thousands, except per share data)
	£			£			£			£
Research and development expenses		(6,769	)		(3,959	)		(13,552	)		(10,764	)
Administrative expenses		(1,509	)		(1,754	)		(3,090	)		(3,402	)
Net foreign exchange (losses) gains		(74	)		(564	)		21			(1,259	)
Operating loss		(8,352	)		(6,277	)		(16,621	)		(15,425	)
Finance income		85			178			211			465
Loss before tax		(8,267	)		(6,099	)		(16,410	)		(14,960	)
Income tax credit		1,272			685			2,577			1,679
Loss for the period		(6,995	)		(5,414	)		(13,833	)		(13,281	)
Basic and diluted loss per ordinary share		(0.12	)		(0.10	)		(0.25	)		(0.25	)

Unaudited Condensed Consolidated Statements of Financial Position As At

	June 30, 2024			December 31, 2023
	(in thousands)
	£			£
Assets
Non-current assets
Intangible assets		2,214			2,128
Property, plant and equipment		343			521
Deferred tax asset		168			143
	2,725			2,792
Current assets
Prepayments, accrued income and other receivables		2,044			2,671
Current income tax receivable		3,662			5,123
Cash and cash equivalents		11,639			17,225
		17,345			25,019
Total assets		20,070			27,811
Equity and liabilities
Capital and reserves
Share capital and share premium		144,870			143,420
Other reserves		78,373			79,173
Accumulated deficit		(219,443	)		(207,706	)
Total equity attributable to equity holders of the Company		3,800			14,887
Non-current liabilities
Provisions		58			58
Lease liabilities		154			190
	212			248
Current liabilities
Trade payables		6,108			3,375
Payroll taxes and social security		164			155
Accrued expenditure		9,659			8,940
Lease liabilities		127			206
	16,058			12,676
Total liabilities		16,270			12,924
Total equity and liabilities		20,070			27,811

Unaudited Condensed Consolidated Statements of Cash Flows

	For the Six Months Ended June 30,
	2024			2023
	(in thousands)
	£			£
Cash flows from operating activities
Loss for the period		(13,833	)		(13,281	)
Adjustments for:
Income tax credit		(2,577	)		(1,679	)
Amortization and depreciation		272			288
Movement in provisions		—			(1,109	)
Finance income		(211	)		(465	)
Interest expense on lease liabilities		10			16
Share-based payments		1,292			2,195
Net foreign exchange (gains) losses		(112	)		1,285
		(15,159	)		(12,750	)
Movements in working capital:
Decrease in prepayments, accrued income and other receivables		625			1,288
Increase (decrease) in trade payables		2,734			(124	)
Increase (decrease) in payroll taxes, social security and accrued expenditure		725			(4,598	)
Movements in working capital		4,084			(3,434	)
Cash used in operations		(11,075	)		(16,184	)
Net income tax received (paid)		4,015			(2	)
Net cash used in operating activities		(7,060	)		(16,186	)
Cash flows from investing activities
Interest received		218			482
Payments for property, plant and equipment		(3	)		(5	)
Payments for intangible assets		(176	)		(291	)
Net cash from investing activities		39			186
Cash flows from financing activities
Payments for lease liabilities		(127	)		(84	)
Proceeds from issue of share capital – exercise of share options		3			1
Proceeds from issue of share capital		1,492			11
Share issue expenses		(45	)		(2	)
Net cash from (used in) financing activities		1,323			(74	)
Net decrease in cash and cash equivalents		(5,698	)		(16,074	)
Cash and cash equivalents at beginning of period		17,225			41,912
Effect of exchange rate changes on cash and cash equivalents		112			(1,194	)
Cash and cash equivalents at end of period		11,639			24,644

For more information, please contact:

NuCana plc

Hugh S. Griffith

Chief Executive Officer

+44 131-357-1111

info@nucana.com

ICR Westwicke

Chris Brinzey

+1 339-970-2843

chris.brinzey@westwicke.com